[go: up one dir, main page]

BG101158A - Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания - Google Patents

Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания

Info

Publication number
BG101158A
BG101158A BG101158A BG10115897A BG101158A BG 101158 A BG101158 A BG 101158A BG 101158 A BG101158 A BG 101158A BG 10115897 A BG10115897 A BG 10115897A BG 101158 A BG101158 A BG 101158A
Authority
BG
Bulgaria
Prior art keywords
estrogen
establishment
regimen
antagonist
dosage
Prior art date
Application number
BG101158A
Other languages
English (en)
Other versions
BG63363B1 (bg
Inventor
Gary HODGEN
Audrey Philips
Original Assignee
Eastern Virginia Medical School
Ortho Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG101158(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Eastern Virginia Medical School, Ortho Pharmaceutical Corporation filed Critical Eastern Virginia Medical School
Publication of BG101158A publication Critical patent/BG101158A/bg
Publication of BG63363B1 publication Critical patent/BG63363B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Установяването на режим за терапевтично лечение на гонадостероиднозависимо състояние при млекопитаещи включва понижаване подаването на естроген чрез прилагане на антагонист на освобождаващ гонадотропинхормон в количество, ефективнода инхибира пролиферацията на ендометриума, без да спира продукциятана ендогенен естроген. Изобретението се отнася и до метод за установяване на това дали пониженото подаване на естроген при даден индивид е такова, чеконцентрацията наестрадиол е потисната до оптимално ниво, подходящо за терапевтично лечение на гонадо-стероиднозависимо състояние като ендометриоза виндивида, чрез прилагането на антагонист на освобождаващ гонадотропинхормон с дадена дозировка. Методътвключва индивидуално определяне на дозировката,например чрез провеждането на прогестеронпровокиращ тест и определяне оптимален режим и доза на антагониста на освобождаващ гонадотропинхормон.
BG101158A 1994-07-22 1997-01-21 Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания BG63363B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number Publication Date
BG101158A true BG101158A (bg) 1997-09-30
BG63363B1 BG63363B1 (bg) 2001-11-30

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101158A BG63363B1 (bg) 1994-07-22 1997-01-21 Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания

Country Status (29)

Country Link
EP (1) EP0769956B1 (bg)
JP (1) JP3138477B2 (bg)
CN (1) CN1137722C (bg)
AP (1) AP775A (bg)
AT (1) ATE190494T1 (bg)
AU (1) AU691952B2 (bg)
BG (1) BG63363B1 (bg)
BR (1) BR9508718A (bg)
CA (1) CA2195745C (bg)
CY (1) CY2228B1 (bg)
CZ (1) CZ291803B6 (bg)
DE (1) DE69515666T2 (bg)
DK (1) DK0769956T3 (bg)
EE (1) EE03515B1 (bg)
ES (1) ES2145286T3 (bg)
FI (1) FI970244L (bg)
GR (1) GR3033590T3 (bg)
HU (1) HU218910B (bg)
IL (1) IL114655A (bg)
IS (1) IS4413A (bg)
LV (1) LV11823B (bg)
MX (1) MX9700574A (bg)
NO (1) NO970257L (bg)
NZ (1) NZ290554A (bg)
OA (1) OA10730A (bg)
PT (1) PT769956E (bg)
RU (1) RU2181598C2 (bg)
SK (1) SK282118B6 (bg)
WO (1) WO1996003138A1 (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
IL148185A0 (en) * 1999-09-23 2002-09-12 Zentaris Ag Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
CA2726247C (en) * 2008-05-29 2018-06-26 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
DK3297631T3 (da) * 2015-05-18 2019-11-11 Nerre Therapeutics Ltd NK-1/NK-3-receptorantagonist til behandling af hedeture
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
NO970257D0 (no) 1997-01-21
NO970257L (no) 1997-01-21
ATE190494T1 (de) 2000-04-15
AP9700913A0 (en) 1997-01-31
HU9700046D0 (en) 1997-02-28
ES2145286T3 (es) 2000-07-01
IL114655A (en) 2005-08-31
MX9700574A (es) 1997-12-31
CA2195745C (en) 2005-03-29
IS4413A (is) 1997-01-14
AU3132095A (en) 1996-02-22
IL114655A0 (en) 1995-11-27
LV11823B (en) 1998-03-20
DK0769956T3 (da) 2000-06-05
EE9700208A (et) 1998-02-16
CN1200674A (zh) 1998-12-02
JP3138477B2 (ja) 2001-02-26
SK7097A3 (en) 1997-11-05
PT769956E (pt) 2000-07-31
CZ291803B6 (cs) 2003-06-18
WO1996003138A1 (en) 1996-02-08
BG63363B1 (bg) 2001-11-30
SK282118B6 (sk) 2001-11-06
NZ290554A (en) 2000-08-25
CN1137722C (zh) 2004-02-11
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
JPH10503203A (ja) 1998-03-24
EE03515B1 (et) 2001-10-15
CA2195745A1 (en) 1996-02-08
HUT77127A (hu) 1998-03-02
LV11823A (lv) 1997-08-20
AP775A (en) 1999-10-28
EP0769956B1 (en) 2000-03-15
DE69515666D1 (de) 2000-04-20
EP0769956A1 (en) 1997-05-02
AU691952B2 (en) 1998-05-28
DE69515666T2 (de) 2000-07-06
FI970244A0 (fi) 1997-01-21
HU218910B (hu) 2000-12-28
FI970244L (fi) 1997-01-21
CY2228B1 (en) 2003-04-18
BR9508718A (pt) 1997-12-30
OA10730A (en) 2001-06-07
CZ15097A3 (en) 1997-11-12
RU2181598C2 (ru) 2002-04-27

Similar Documents

Publication Publication Date Title
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
NO975586L (no) Transdermal innretning og fremgangsmåte for administrering av 17-deacetyl norgestimat alene eller i kombinasjon med et östrogen
UA66772C2 (uk) Спосіб лікування або полегшення ішемії міокарда (варіанти) та препарат прогестерону для використання у вказаній терапії (варіанти)
LT96133A (en) Remedy for treatment of ovarian estrogen dependent conditions
MX9803563A (es) Preparacion terapeutica para la administracion transdermica de principios activos.
NZ221991A (en) Device for the transdermal delivery of progesterone, estradiol esters and mixtures thereof; and compositions therefor
NZ244499A (en) Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth
BG102668A (bg) Използване на рраr-алфа и рраr-гама за лечение насиндром х
EP0136011A3 (en) A method of hormonal treatment of peri-menopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
YU54602A (sh) Drospirenon za terapiju zamene hormona
GR3033667T3 (en) Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure
TAUBENHAUS et al. Hormonal interaction in the regulation of granulation tissue formation
BG101158A (bg) Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания
DE69831241D1 (de) Gonadotropin releasing hormon antagonist
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
BG101427A (bg) Метод за контрол на женски фертилитет
EP0788799A3 (en) LHRH-Antagonists in the treatment of fertility disorders
ATE342721T1 (de) Steroide als neurochemische stimulatoren des nasenraumes zur linderung der prämenstrualen symptome
JO1879B1 (en) Consolidation of the secretion of ovarian estrogen for prolonged treatment regimens
RU97102759A (ru) Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения
Nishino et al. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1, 4-diene-3, 17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors
Boehm et al. Does corpus luteum function autonomously during estrous cycle in the rat? A possible involvement of LH and prolactin
JPS5225291A (en) Fixing or tightening fittings for wire, etc.
Ehrmann et al. Gonadotropin-releasing hormone agonist testing of pituitary-gonadal function